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Abstract 
Background: Glioblastoma multiforme (GBM) is the most common and lethal brain tumor in adults, highlighting the 
need for novel treatment strategies. Patient derived xenografts (PDX) represent a valuable tool to accomplish this task.
Methods: PDX were established by implanting GBM tissue subcutaneously. Engraftment success was compared 
between NMRI Foxn1nu and NOD/SCID as well as between fresh and cryopreserved tissue. Established PDX were 
analyzed histologically and molecularly. Five PDX were experimentally treated with different drugs to assess their 
potential for preclinical drug testing.
Results: Establishment of PDX was attempted for 36 consecutive GBM cases with an overall success rate of 22.2% in 
NMRI Foxn1nu mice. No difference was observed between fresh or cryopreserved (20–1057 days) tissue in direct com‑
parison (n = 10 cases). Additionally, engraftment was better in NOD/SCID mice (38.8%) directly compared to NMRI 
Foxn1nu mice (27.7%) (n = 18 cases). Molecular data and histology of the PDX compare well to the primary GBM. The 
experimental treatment revealed individual differences in the sensitivity towards several clinically relevant drugs.
Conclusions: The use of vitally frozen GBM tissue allows a more convenient workflow without efficiency loss. NOD/
SCID mice appear to be better suited for initial engraftment of tumor tissue compared to NMRI Foxn1nu mice.
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Background
Glioblastoma multiforme (GBM) is the most common 
primary brain tumor in adults [1, 2]. With a median sur-
vival of 14–16 months from diagnosis, the prognosis for 
GBM patients is very dismal and novel therapeutic strat-
egies are urgently needed to combat this disease [3–6]. A 
promising approach is to further facilitate personalized 
therapy regimens, which are tailored to specific molecu-
lar alterations of individual tumors. Besides methylation 
status of the MGMT promoter, established prognos-
tic parameters for GBM are missing [7]. However, with 
next generation sequencing techniques on the rise, more 
detailed analyses of cancer genomes are becoming rou-
tinely available to clinicians and researchers worldwide 
[8, 9]. For example, previous analyses of GBM genomes 
revealed several common alterations in tyrosine kinase 
signaling (e.g. mutations or amplification of EGFR, 
ERBB2, PDGFRA, MET and PTEN) [10]. Several tyrosine 
kinase inhibitors and other targeted drugs entered clini-
cal trials for GBM treatment (e.g. vandetanib, bevaci-
zumab, nimotuzumab) however, with so far unsatisfying 
outcome [11–13].
In order to accomplish better personalized therapy 
strategies, individual models of GBM and sufficient 
amounts of tumor material for detailed molecular and 
functional analyses are required.
Although the generation of individual in  vitro models 
of GBM is feasible with success rates of cell culture estab-
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several disadvantages. Due to enhanced clonal selection 
in vitro, the use of (ultra-) low passage cell lines is man-
datory to best preserve intratumoral heterogeneity [15]. 
Additionally, during in  vitro culture, several genomic 
aberrations, e.g. amplification of EGFR, which are pre-
sent in the primary tumor, are not maintained [16, 17]. 
In contrast, intratumoral heterogeneity and genomic 
aberrations are well maintained in heterotopic or ortho-
topic patient derived in vivo models of GBM [18, 19]. The 
establishment of such PDX models requires optimized 
logistics and standardized protocols; further the com-
bined expertise from different fields (surgery, molecular 
biology and animal care facility) is imperative. In this 
study, we present a feasible method for the establishment 
of GBM PDX models from patient tumor material. First, 
we investigated the success rates of PDX establishment 
using cryopreserved GBM tissue (postoperative immedi-
ately frozen) compared to fresh tumor tissue. We could 
demonstrate that cryopreservation with subsequent long 
term storage of GBM tissue at ultra-low temperatures is 
a suitable and logistically convenient method for xeno-
grafting at a later time point. Furthermore, we compared 
the success rates of PDX establishment using two differ-
ent immunocompromised mouse strains (NMRI Foxn1nu 
and NOD/SCID) in order to further optimize PDX 
creation. Once established, PDX models may be a suit-
able tool for the prediction of therapy outcomes as well 
as planning of patient individual treatments in order to 
identify the best possible therapy option for patients suf-
fering from GBM.
Methods
Tumor specimen collection and cryopreservation
Tumor tissue was collected directly from the opera-
tion theater at the department of neurosurgery at the 
University Medicine of Rostock. Specimen collection 
was conducted in accordance with the ethics guidelines 
for the use of human material, approved by the Eth-
ics Committee of the University of Rostock (Reference 
number: A 2009/34) and with informed written con-
sent from all patients prior to surgery. Tumor tissue was 
cut with sterile scalpels to small tissue cubes (approxi-
mately 3  ×  3  ×  3  mm). For cryopreservation, 4 tumor 
cubes were transferred to a sterile cryo-tube containing 
1.5  mL freezing medium (fetal calf serum, 10% DMSO) 
and immediately frozen at −80 °C in a freezing container. 
Vitally frozen tumor material was transferred after over-
night cooling at −80 °C into liquid nitrogen for long term 
storage at ultra-low temperatures.
Xenografting
Tumor tissue cubes were implanted subcutaneously into 
the flanks of female 6–8  weeks old NMRI Foxn1nu or 
NOD/SCID mice under anaesthesia (Ketamine/Xylazin 
90/6 mg/kg Bw) as previously described [20–22]. Briefly, 
cryopreserved tumor tissue was thawed at 37  °C and 
washed with PBS prior to subcutaneous implantation.
Care and housing of the animals was provided at the 
animal facilities of the University Medicine Rostock in 
accordance with recommendations from the Guide for 
the Care and Use of Laboratory Animals of the National 
Institutes of Health. The procedure was approved by 
the Committees on the Ethics of Animal Experiments 
(Landesamt für Landwirtschaft, Lebensmittelsicherheit 
und Fischerei Mecklenburg-Vorpommern; permission 
number: 7221.3-1.1-083/11). Mice were kept in a spe-
cific pathogen free environment and exposed to 12  h 
light/12 h darkness cycles with standard food and water 
(supplemented with Co-trimoxazol for 6 weeks after sur-
gery) ad libitum. Mice were sacrificed when tumors grew 
to a volume of 1  cm3 and tumor material was collected 
for further studies or passaged further in NMRI Foxn1nu 
mice.
For the establishment of orthotopic GBM PDX, a single 
cell suspension derived from previously established GBM 
PDX was injected into the brain of NOD/SCID mice. 
Upon first signs of extracerebral tumors at place of cell 
injection or abnormal behavior, the mice were sacrificed 
and the brains were snap frozen for further analysis.
Experimental treatment of tumor bearing mice
The chemotherapeutic response of the PDX models was 
determined in female NMRI nu/nu mice (Janvier, Le 
Genest-Saint-Isle, France). Once tumors became palpa-
ble, tumor size and body weight were measured twice 
a week. Tumor volumes (V) were calculated by the for-
mula V = (length × width2)/2 and related to the values at 
the first day of treatment (relative tumor volume, RTV). 
Median treated to control (T/C) values of RTV was used 
for the evaluation of each treatment modality.
When the mean tumor volume reached the indi-
cated starting volume (80–120  mm3), mice were rand-
omized to the six treatment arms (five mice per group) 
and treatment was started. If not mentioned otherwise, 
the following drugs and modalities were used in the sin-
gle treatment studies: everolimus 5  mg/kg, orally, (days 
1–5)  ×  2; sorafenib 80  mg/kg, orally, (days 1–5)  ×  2; 
bevacizumab 10 mg/kg, intraperitoneally, (three times a 
week)  ×  2; irinotecan 15  mg/kg, intraperitoneally, days 
1–5; salinomycin 10  mg/kg, orally, days 1–14; temozo-
lomide 90  mg/kg, orally, days 1–5. Control mice were 
treated with the vehicle alone (saline), orally. Doses and 
schedules were chosen according to previous experi-
ence in animal experiments and represent the maximum 
tolerated or efficient doses. The injection volume was 
0.2 mL/20 g body weight.
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EGFR copy number analysis
Genomic DNA (gDNA) from snap frozen tumor tissue 
was isolated using the Wizard Genomic DNA Purifica-
tion Kit (Promega, Mannheim, Germany) according to 
the manufacturer’s instructions. EGFR copy number was 
determined by quantitative PCR on a StepOne Realtime 
PCR system (Applied Biosystems, Darmstadt, Germany) 
with SensiFastSYBR Hi-Rox-Kit (Bioline, Luckenwalde, 
Germany) in triplicates. Commercial normal human 
gDNA (Promega) served as calibrator and the repetitive 
element LINE1 as endogenous control. The EGFR copy 
number was calculated with the Ct-algorithm.
MGMT promoter methylation analysis
MGMT promoter methylation was analyzed with the 
MethyLight method [23]. Briefly, gDNA was subject 
to bisulfide conversion using the Epitect Bisulfite Kit 
(Qiagen, Hilden, Germany) according to the manufac-
turer’s recommendations. Quantitative PCR was per-
formed with the SensiFast Probe HiRox Kit (Bioline) and 
a primer/probe combination specific for the methylated 
MGMT promoter sequence (Additional file  1). Fully 
methylated SSSI treated DNA served as calibrator and 
the collagenase gene 2A1 (COL2A1) served as endog-
enous control. The percentage of methylated reference 
(PMR) value was calculated by dividing the MGMT/
COL2A1 ratio of the sample by the MGMT/COL2A1 
ratio of the SSSI-treated DNA multiplied by 100. Samples 
with a PMR value >4 were considered as methylated.
Mutation analysis
All samples were analyzed for mutations in the fol-
lowing loci: IDH1 R132 (exon 4), IDH2 R172 (exon 4), 
BRAF V600 (exon 15), KRAS G12, G13 (exon 2) and 
Q61 (exon 3) and TP53 exons 5–8. The desired genomic 
regions were amplified by PCR (Additional file  1). The 
PCR products were purified and used as template for 
Sanger sequencing using BigDye® Terminator v1.1 Cycle 
Sequencing Kit (Applied Biosystems) according to the 
manufacturer’s protocol. The sequencing products were 
purified using the BigDye XTerminator® Purification Kit 
and analysed with the 3500 genetic analyzer system using 
the SeqScape® Software v2.7 (all Applied Biosystems).
Genetic fingerprint analysis
A genetic fingerprint analysis was performed by PCR 
using 9 different loci (D5S818, D7S820, D16S539, 
D13S317, Amelogenin, vWA, TPOX, TH01 and CSF1; 
Additional file  1) to verify the identity of the PDX in 
comparison to original GBM material [24]. Briefly, 
25  ng DNA of each sample were used in 2 multiplex 
PCR reactions (cycling conditions: initial denaturation 
at 96  °C for 2 min, 30 cycles of 94  °C 30 s, 59  °C 2 min 
and 72 °C 1.5 min, 60 °C for 45 min). PCR products were 
diluted tenfold and subsequently analyzed by capillary 
electrophoresis.
Immunohistochemistry and H&E‑staining
Formaldehyde fixed tissue samples were processed using 
the ExcelsiorAS system (ThermoScientific) according to 
the manufacturer’s recommendations. For GFAP immu-
nohistochemistry a ready to use anti-GFAP primary 
antibody (Dako, Hamburg, Germany) was used and the 
samples were processed on an automated system, EnVi-
sion™ FLEX (Dako), following manufacturer’s instruc-
tions. Hematoxylin and Eosin staining was performed 
following established standard protocols [25].
Statistics
Statistical analysis was performed using SigmaPlot 
10.0 (Systat Software). Tumor volumes were compared 
between treatment and control groups at the end of the 
experiment and analyzed by unpaired t test.
Results
Engraftment of primary tumor samples 
in immunocompromized mice
Overall, 42 tumor samples were collected and subse-
quently cryopreserved. Out of all samples 36 samples 
were classified as GBM (WHO°IV), 5 as astrocytomas 
(WHO°I–III) and 1 an anaplastic oligodendroglioma 
(WHO°III). Information on patient characteristics, diag-
nosis, and molecular alterations of the tumors is summa-
rized in Table 1 and Additional file 2.
Cryopreserved tissue samples of all cases were 
implanted bilaterally subcutaneously in the flanks of 
female 6–8 weeks old NMRI Foxn1nu mice. Cryopreser-
vation periods of the tumor samples ranged from 20 to 
1057 days. Engraftment of frozen GBM samples was suc-
cessful in 8 out of 36 cases (22.2%) (Table 1). Engraftment 
of the 5 astrocytoma samples and the anaplastic oligo-
dendroglioma sample was not successful (Additional 
file 2).
For 10 GBM cases, a direct comparison of tumor take 
rate between cryopreserved tumor tissue and tumor tis-
sue freshly received from the operation theater was per-
formed (Table  1). Engraftment of cryopreserved tumor 
tissue in NMRI Foxn1nu mice was successful in one case 
out of 10 (HROG52, 10.0%); identical to engraftment of 
fresh tumor tissue (HROG59, 10.0%). In 2 cases the initial 
tumor growth of fresh GBM tissue was followed by com-
plete spontaneous regression (HROG58 and HROG60). 
Thus, within this limited number of cases, there was no 
difference between engraftment success of cryopreserved 
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Table 1 Overview of GBM patient characteristics, molecular alterations, cryoperiod of the samples prior to subcutaneous 
implantation and outcome of PDX establishment attempts in NMRI Foxn1nu mice
Sample ID Sex/age Molecular alterations Cryoperiod (days) Engraftment
HROG02 M/68 P53 (R248Q), 3xEGFR, MGMT(M) 305 –
HROG04 F/53 36xEGFR, MGMT(U) 270 –
588 –
826 –
HROG05 F/60 82xEGFR, K‑ras (G12D), MGMT(M) 268 ✓
HROG06 M/53 P53 (R273H, R306*), 82xEGFR, MGMT(U) 260 –
570 ✓
HROG07 M/55 12xEGFR, MGMT(U) 143 –
699 –
HROG10 M/74 MGMT(U) 71 –
627 –
HROG11 F/54 P53 (R248Q), 3xEGFR, MGMT(U) 56 –
HROG12 M/64 36xEGFR, MGMT(U) 307 ✓
HROG13 F/77 MGMT(U) 318 –
529 ✓
HROG15 M/56 n.d. 240 –
HROG16 M/53 MGMT(U) 237 –
HROG17 M/70 3xEGFR, MGMT(M) 194 ✓
HROG19 M/69 8xEGFR, MGMT(U) 217 –
HROG21 M/44 IDH1 (R132H), MGMT(U) 192 –
HROG22 M/66 MGMT(M) 167 –
HROG23 F/60 BRAF (V600E), MGMT(U) 191 –
1057 –
HROG24 F/73 P53 (R273C), 42xEGFR, MGMT(U) 112 –
350 –
HROG25 F/77 MGMT(U) 117 –
HROG31 F/59 MGMT(U) 55 –
214 –
HROG32 F/76 44xEGFR, MGMT(U) 125 –
HROG33 F/46 31xEGFR, MGMT(U) 119 ✓
HROG34 F/69 96xEGFR, MGMT(U) 133 –
HROG36 F/80 MGMT(U) 80 –
HROG38 F/49 MGMT(U) 58 –
236 –
HROG41 M/71 IDH1 (R132H), MGMT(M) 31 –
209 –
HROG42 F/70 MGMT(U) 30 –
189 –
HROG49 M/45 MGMT(U) Fresh –
360 –
HROG52 M/47 n.d. Fresh ✓
308 –
HROG54 M/58 MGMT(M) Fresh –
281 –
HROG55 F/74 MGMT(M) Fresh –
278 –
HROG56 F/76 MGMT(U) Fresh –
222 –
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and fresh GBM tissue samples. Furthermore, success 
rates of engraftment in NMRI Foxn1nu mice or in NOD/
SCID mice were compared on the basis of 18 cryopre-
served GBM samples (Table 2). In NMRI Foxn1nu mice, 
5 out of 18 samples were successfully engrafted (27.7%). 
The success rate was higher in NOD/SCID mice (7 out 
of 18 samples; 38.8%). Four cases (HROG05, HROG06, 
HROG13 and HROG17) were successfully engrafted 
in both mouse strains, two cases could only be success-
fully engrafted in NOD/SCID mice and one case only 
engrafted in NMRI Foxn1nu mice (Table 2).
Long‑term stability of GBM PDX models
All initially successfully engrafted cases, both in NMRI 
Foxn1nu and NOD/SCID mice, were passaged in  vivo 
to determine if these PDX models demonstrate stable 
growth behavior. PDX models initially established in 
NOD/SCID mice (Table  2) were transferred in NMRI 
Foxn1nu mice (Additional file 3). 9 out of the 11 initially 
positive PDX cases (81.8%) were successfully engrafted 
in the first in  vivo transfer and subsequently passaged 
further. Two initially positive cases (HROG12 and 
HROG52) were unable to form a tumor in subsequent 
in vivo transfers into NMRI Foxn1nu mice. In the case of 
HROG12, a second in vivo transfer attempt also failed. To 
date, 6 GBM PDX cases reached a minimum of 5 in vivo 
passages and therefore are considered as long-term sta-
ble PDX models (Additional file 3). The remaining cases 
HROG17, HROG33 and HROG38 have reached 3 or 4 
passages and thus will very likely become long-term sta-
ble PDX models as well. Overall, a strong trend towards 
accelerated tumor growth was observed with increasing 
in vivo passage number (Table 3).
Morphology of primary GBM and their PDX derivates is 
conserved over several in vivo passages
As shown for HROG33 and HROG59 in two consecu-
tive in vivo passages (designated as “PDX-T1” and “PDX-
T2”), the PDX models resemble the respective primary 
GBM closely (Fig. 1). The HROG33 PDX models show a 
slightly higher compactness of cell structure than the pri-
mary tumor, but important characteristics such as con-
tent of mitotic cells, degree of pleomorphy and necrosis 
compare well with the primary tumor. Albeit the limited 
sample size of the PDX, both passages of HROG33 PDX 
fulfilled formal requirements which would have allowed 
a correct GBM diagnosis. The HROG59 PDX models 
also show key characteristics of the primary tumor (high 
Table 1 continued
Sample ID Sex/age Molecular alterations Cryoperiod (days) Engraftment
HROG58 F/57 MGMT(U) Fresh –
165 –
HROG59 M/60 16xEGFR, MGMT(U) Fresh ✓
152 –
HROG60 M/51 2xEGFR, MGMT(U) Fresh –
126 –
513 –
HROG63 M/48 18xEGFR, MGMT(U) Fresh –
20 –
HROG64 F/57 MGMT(M) Fresh –
20 –
M male, F female, xEGFR EGFR gene amplification, MGMT(M) methylated MGMT promoter, MGMT(U) unmethylated MGMT promoter, n.d. not determined
Table 2 Direct comparison of  PDX establishment success 
between NMRI Foxn1nu and NOD/SCID mice
Overview of PDX establishment success of 18 cases, checkmarks indicate 
successful engraftment
Sample ID Cryoperiod (days) NMRI Foxn1nu NOD/SCID
HROG02 305–1963 – –
HROG04 270–1213 – –
HROG05 268–1248 ✓ ✓
HROG06 260–1918 ✓ ✓
HROG07 143–1123 – ✓
HROG10 71–1763 – –
HROG13 318–1634 ✓ ✓
HROG15 240–1570 – –
HROG17 194–1555 ✓ ✓
HROG19 217–1570 – –
HROG21 192–900 – –
HROG22 167–875 – ✓
HROG23 191–1057 – –
HROG24 112–1494 – –
HROG25 177–912 – –
HROG38 58–1500 – ✓
HROG49 0–638 – –
HROG59 0–427 ✓ –
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degree of pleomorphy, necrosis and content of hyper-
chromatic cells). Of the two HROG59 PDX transfers, 
only HROG59 PDX-T2 formally fulfils the requirements 
for a GBM diagnosis. The specific section of HROG59 
PDX-T1 does–most likely due to the small sample size—
not contain a thrombotic blood vessel and thus, does 
not fulfil all formally required characteristics for a GBM 
diagnosis; yet compares very well to the primary tumor 
otherwise.
In general, the PDX models show a highly similar mor-
phology between first and second in  vivo passage. As 
compared to the respective primary GBM, important 
characteristics were conserved in the PDX models in 
these low passages. However, the heterotopic PDX do not 
show invasive growth behavior, which is characteristic 
for GBM. Invasive growth into surrounding tissue was 
observed in orthotopic models of two exemplary cases 
(HROG06 and HROG59; Additional file 4). High expres-
sion of glial fibrillary acidic protein (GFAP), a marker for 
astrocytic cells, is evident in both primary tumors and 
the corresponding heterotopic PDX models in both pas-
sages (Additional file 5). This additionally verifies that the 
GBM PDX models conserve their neuronal character.
Comparison of molecular aberrations between primary 
GBM and corresponding PDX
The presence of mutations found in the primary tumor 
was analyzed in every corresponding PDX model 
(Table 1; Additional file 2). In all cases, the mutations in 
the genes K-RAS, P53 and IDH1 could be confirmed in 
the PDX models. However, analyses of MGMT promoter 
methylation status of primary GBM and derived PDX 
models revealed differences in 2 out of 9 cases (Table 3). 
Furthermore, genomic amplification of EGFR was vari-
able in the PDX models over several in vivo passages as 
well as in comparison to the primary GBM in all cases 
with EGFR amplification in the primary tumor. GBM 
cases without EGFR amplification did not gain additional 
EGFR gene copies over the PDX passages. Identity of all 
PDX models was verified by genetic fingerprint analyses 
(Additional file 6) and matched in all cases.
Experimental therapy of GBM PDX models
Five different GBM PDX models were experimentally 
treated with monotherapies of temozolomide, everoli-
mus, sorafenib, salinomycin, bevacizumab or irinote-
can (5 mice per group). Control mice were treated with 
physiological saline solution. 4 out of 5 PDX models were 
highly susceptible to temozolomide monotherapy, only 
HROG05 showed intrinsic temozolomide resistance 
(Fig. 2). Good treatment results were also obtained with 
the anti-VEGF antibody bevacizumab, which had a posi-
tive effect in all cases tested. Irinotecan, a topoisomerase 
inhibitor, was effective in 3 cases (HROG05, HROG13 
and HROG59). Treatment with the mTOR inhibitor 
everolimus had positive effects in 2 cases (HROG05 
and HROG13). The multi-kinase inhibitor sorafenib was 
Table 3 Analysis of  MGMT promoter methylation 
and EGFR amplification of GBM tumors and corresponding 
PDX over several in vivo passages
M methylated, U unmethylated, PMR percentage of methylated reference







Tumor M (34,5) 82× –
PDX P2 U (0) 12× 60
HROG06
Tumor U (0) 82× –
PDX P0 U (0) 75× 54
PDX P1 U (0) 69× 24
PDX P2 U (0) 103× 40
PDX P3 U (0) 123× 27
PDX P4 U (0) 144× 25
PDX P5 U (0) 147× 19
HROG07
Tumor U (0) 12× –
PDX P2 U (0) 152× 82
PDX P4 U (0) 96× 98
HROG12
Tumor U (1,4) 37× –
PDX P0 U (0) 52× 123
HROG13
Tumor U (3,9) 1× –
PDX P1 M (4) 2× 25
PDX P2 M (5) 2× 31
PDX P3 M (15) 2× 46
HROG17
Tumor M (14) 4× –
PDX P2 M (11) 1× 59
HROG22
Tumor M (22,2) 1× –
PDX P0 M (6) 2× 158
PDX P1 M (22) 2× 54
PDX P3 M (73) 1× 46
PDX P5 M (97) 2× 26
HROG33
Tumor U (0) 31× –
PDX P1 U (0) 67× 90
HROG59
Tumor U (0) 16× –
PDX P2 U (0) 85× 68
PDX P3 U (0) 92× 31
PDX P4 U (0) 47× 31
PDX P5 U (0) 36× 54
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effective only in one case (HROG22) and salinomycin 
treatment had no effect in all cases tested. Additionally, 
all experimentally treated PDX models were analyzed 
for potentially relevant mutations by panel sequencing 
covering 212 target regions in 48 cancer related genes 
(Table 4).
Discussion
Glioblastoma multiforme remains a tumor difficult to 
treat with a very dismal prognosis. Hence, gaining a better 
understanding of molecular characteristics of individual 
GBM is mandatory for the development of individualized 
therapy strategies. This task requires sufficient amounts 
of tumor material for analysis and—potentially—therapy 
response prediction approaches. Individual GBM PDX 
recommend themselves for this purpose, since tumor 
material can be propagated for further studies in an 
in  vivo environment, while maintaining intratumoral 
heterogeneity as well as most genomic aberrations [26]. 
However, establishment of GBM PDX requires optimized 
logistics and standardized protocols. We demonstrate 
here that GBM tissue cryopreserved and subsequently 
stored for longer time periods enables xenografting at 
a later time point. Additionally, and to the best of our 
knowledge, this is the first study in which xenografting 
of fresh and vitally frozen GBM tissue was compared 
directly. We did not observe a difference of engraftment 
success between fresh and vitally frozen GBM tumor 
Fig. 1 Hematoxylin and eosin staining of paraffin embedded GBM and PDX sections. A HROG33 primary GBM, B HROG33 PDX after first in vivo 
transfer, C HROG33 PDX after second in vivo transfer, D HROG59 primary GBM, E HROG59 PDX after first in vivo transfer, F HROG59 PDX after second 
in vivo transfer. 200‑fold magnification
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Fig. 2 Experimental treatment outcomes of 5 GBM PDX. Development of relative tumor volumes over time, error bars indicate the standard errors 
of the mean. *p < 0.005, ***p < 0.001, p‑values were calculated with a t test at the end of the experiment in comparison to untreated controls. ctr 
control treated with PBS, Eve everolimus, Sor sorafenib, Bev bevacicumab, Iri irinotecan, Sal salinomycin, Tem temozolomide
Table 4 Mutations in PDX models used for in vivo therapy experiments
Mutations identified by amplicon panel sequencing covering 212 target regions in 48 cancer-related genes (Illumina MiSeq TSACP (Illumina Variant Caller 3.1.10.0)). 
Del: deletion, fs*: frame shift leading to stop, *: stop gain
Sample ID Mutations in PDX
HROG05 EGFR (R108K, Y626H), K‑Ras (G12D), P53 (R280K)
HROG07 APC (A1340 V), FLT3 (V592I), PIK3CA (E545K), PTPN11 (S502L)
HROG13 ABL1 (A288S), ATM (F858L), ERBB2 (G748C), GNA11 (N336K), PTEN (S207C), VHL (E94*)
HROG22 PIK3CA (E545K), PTPN11 (S502L)
HROG59 ERBB2 (Del fs*), GNAQ (2x Del fs*), KDR (Q472H), PTEN (Q17L, M198I, L265I)
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material. Hence, many logistic obstacles (e.g. transport 
conditions and transport time of tumor tissue, availabil-
ity of mice for xenografting, opening hours at laboratory 
animal facilities) can be circumvented by using this sim-
ple and feasible method of GBM tissue cryopreservation. 
However, we did not observe successful engraftment of 
both fresh and vitally frozen GBM tissue derived from 
an identical primary GBM tumor. Although this was not 
subject of further investigation, it seems likely that the 
quality of implanted tumor tissue—fresh or vitally fro-
zen—as well as individual and yet unknown mouse fac-
tors have an influence on the success of an individual 
tumor graft [27].
Overall engraftment success in NMRI Foxn1nu mice 
is with 22.2% rather low in comparison to successful 
establishment of GBM cell lines [14], orthotopic GBM 
PDX [18] or of PDX from other tumor entities [22], 
but well in line with previous reports from other stud-
ies on heterotopic GBM [28]. The GBM PDX establish-
ment success rate appears to be higher in NOD/SCID 
mice, which lack B- and T-Lymphocytes as well as NK 
cells, than in NMRI Foxn1nu mice (38.8 vs 27.7% in the 
directly compared 18 cases). Out of all 7 successfully 
engrafted cases in this cohort of 18 cases, 4 cases were 
positive in both mouse strains, 2 cases only engrafted 
in NOD/SCID mice and one case was only successful in 
NMRI Foxn1nu mice. NMRI Foxn1nu mice are a widely 
used host for tumor xenograft studies due to the com-
plete absence of T-Lymphocytes, yet other components 
of the immune system (NK cells, granulocytes, mono-
cytes/macrophages, dendritic cells and B-Lymphocytes) 
are still present. Although residual active immune cells 
in NMRI Foxn1nu mice likely play a role in prevent-
ing tumor formation, other crucial parameters like the 
quality of the implanted tumor tissue, the biology of the 
individual tumors and the individual mice are likely to 
play an even greater role [27]. In three cases (HROG23, 
HROG58, HROG60), we observed initial tumor forma-
tion followed by complete regression of engrafted pri-
mary tumors in NMRI Foxn1nu mice (data not shown) 
before material could be saved for subsequent in  vivo 
passaging. In these cases, engrafting repetitions might 
still result in successful PDX generation as was the case 
for HROG06 and HROG13.
Mutations present in the primary GBM were main-
tained in all analyzed genes in all PDX models over sev-
eral passages. However, genomic amplification of EGFR 
varied between primary GBM and their PDX in nearly 
all cases where EGFR amplification has been observed 
in the primary GBM. Although not further investigated, 
it seems likely that this effect is due to clonal selection 
processes as cells with high EGFR copy numbers are not 
evenly distributed throughout the whole tumor tissue 
[29]. However, we also observed variations in the EGFR 
copy numbers over the PDX passages, which implies that 
cell intrinsic factors are still active.
Nevertheless, PDX models of GBM are valuable tools 
for further studies, for development of novel therapeutics 
as well as response prediction attempts for individualized 
therapy approaches. Intratumoral heterogeneity is gener-
ally well maintained in these models and we could show 
that the morphology of a primary GBM tumor is compa-
rable to its PDX over several passages. However, hetero-
topic PDX do not show invasive growth into surrounding 
tissue compared to orthotopic GBM models. Neverthe-
less, heterotopic (or orthotopic) GBM PDX models using 
cryopreserved tissue specimens are a suitable tool for 
therapy response prediction since this method is fea-
sible to create sufficient amounts of tumor material by 
in vivo passaging in mice to allow systematic and stand-
ardized testing of several therapeutic substances in vivo. 
Responses towards clinically used therapeutics in our test 
series of GBM PDX models were as diverse as expected 
from previous studies but also from clinical experience 
[30, 31]. Generally good in vivo responses were obtained 
with temozolomide, irinotecan and bevacizumab. A com-
bination of these drugs just recently proofed beneficial 
in some cases of unresectable GBM in the neoadjuvant 
setting in a clinical phase II trial [32]. Beside this, two 
out of five PDX models responded to sorafenib and one 
to everolimus. In total, these chemo-response data proof 
applicability and can be considered for targeted selection 
of these novel GBM PDX models in future preclinical 
studies either in the heterotopic or orthotopic setting.
Conclusions
Despite aggressive treatment regimen, GBM remains 
a lethal brain tumor and development of new therapy 
strategies is an urgent task to combat this disease. In 
order to achieve targeted therapy regimen, establish-
ment an analysis of individual in vivo models of GBM 
is essential. Although orthotopic PDX have the advan-
tage of an appropriate tumor microenvironment, het-
erotopic models, as presented in this study, are of high 
value for several reasons. Heterotopic PDX enable the 
production of sufficient amounts of tumor tissue for 
extensive molecular and functional analyses. Further-
more, heterotopic PDX histologically and molecularly 
resemble the primary GBM closely and the establish-
ment of those PDX is technically easily feasible. We 
demonstrated that long term cryopreserved GBM tis-
sue can be engrafted in mice without loss of engraft-
ment efficiency, which allows for a convenient workflow 
and improved logistics. We also systematically com-
pared the PDX establishment success between two 
widely used mouse models, NMRI Foxn1nu and NOD/
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SCID, for 18 GBM cases and found engraftment suc-
cess to be higher in NOD/SCID mice (38.8 vs 27.7% in 
NMRI Foxn1nu mice). However, factors such as quality 
of tumor tissue pieces and individual mice also play a 
role in overall engraftment success, but are not easily 
influenced by the user. Taken together, our data provide 
the means for optimized establishment of GBM PDX 
with regard to choice of mouse strain and use of cryo-
preserved tissue.
Abbreviations
GBM: glioblastoma multiforme; PDX: patient derived xenograft; RTV: relative 
tumour value; Bw: bodyweight.
Authors’ contributions
DW wrote the manuscript, performed fingerprint analyses, participated in sub‑
cutaneous implantation of tumor tissue in NMRI Foxn1nu mice, prepared sam‑
ples for paraffin embedding and molecular analyses. CSM and MK performed 
the majority of subcutaneous tissue implantation in NMRI Foxn1nu mice. BS 
performed the mutation analyses, EGFR amplification analysis and MGMT pro‑
moter methylation analysis. NL analyzed all tissue sections of primary GBMs 
and PDX models. AO and AH performed the subcutaneous implantation of 
tumor tissue in NSG and NMRI Foxn1nu mice as well as experimental treatment 
in vivo. CFC was involved in design and critical review of the manuscript. ML 
designed the study, analyzed the data and wrote the manuscript. All authors 
read and approved the final manuscript.
Author details
1 Children’s Hospital, University Medicine Rostock, Ernst‑Heydemann‑Str. 
8, 18057 Rostock, Germany. 2 Department of Surgery, Molecular Oncology 
Additional files
Additional file 1. Sequences of oligonucleotides and probes.Nucleotide 
sequences and labeling of all oligonucleotides and probes used in this 
study.
Additional file 2. Overview of patient characteristics diagnosed with 
WHO°I–III tumors. Summary of molecular alterations, cryoperiod of the 
samples prior to implantation and the outcome of PDX establishment 
attempts.
Additional file 3. Overview of highest in vivo passages of engrafted 
samples. Given numbers indicate the highest in vivo passage reached 
for given samples, 0 indicates failure at regrafting after initially positive 
engraftment from primary GBM tissue.
Additional file 4. Cresyl violet staining of representative orthotopic GBM 
PDX samples. GBM cells were injected intracranially to establish orthotopic 
GBM PDX models. A‑D) HROG06 31d post injection of 2 × 105 GBM cells, A 
& C) whole brain section for assessment of tumor volume and localization, 
B & D) 100× magnification for assessment of invasive growth of GBM cells 
into surrounding tissue; E & F) HROG59 34d post injection of 8.7 × 105 
GBM cells, F) 100x magnification; G & H) HROG59 34d post injection of 
3.5 × 105 GBM cells, H) 100x magnification.
Additional file 5. GFAP Immunohistochemistry staining of paraffin 
embedded GBM and PDX tissue sections. A) HROG33 primary GBM, 
stained with new fuchsine B) HROG33 PDX after first in vivo transfer, 
C) HROG33 PDX after second in vivo transfer, D) HROG59 primary 
GBM, E) HROG59 PDX after first in vivo transfer, F) HROG59 PDX after 
second in vivo transfer. 200‑fold magnification B‑F were stained with 
3,3′‑Diaminobenzidine.
Additional file 6. Results of genetic fingerprint analysis. Identity verifica‑
tion of all PDX cases over several in vivo passages by genetic fingerprint 
analysis.
and Immunotherapy, University Medicine Rostock, Schillingallee 35, 
18057 Rostock, Germany. 3 Institute of Pathology, University Medicine Rostock, 
Strempelstr. 14, 18057 Rostock, Germany. 4 Experimental Pharmacology 
and Oncology Berlin‑Buch GmbH, Robert‑Roessle‑Str. 10, 13125 Berlin‑Buch, 
Germany. 
Acknowledgements
The authors thank all members of the histopathology lab of the Institute for 
Pathology at the University Medicine of Rostock for paraffin embedding of 
samples, providing tissue sections and immunohistochemistry staining.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
All data generated or analyzed during this study are included in this published 
article [and its supplementary information files].
Ethics approval and consent to participate
Specimen collection was conducted in accordance with the ethics guidelines 
for the use of human material, approved by the Ethics Committee of the Uni‑
versity of Rostock (Reference number: A 2009/34) and with informed written 
consent from all patients prior to surgery.
Animal experiments were approved by the Committee on the Ethics 
of Animal Experiments of the University of Rostock (Landesamt für Land‑
wirtschaft, Lebensmittelsicherheit und Fischerei Mecklenburg‑Vorpommern; 
permission number: 7221.3‑1.1‑083/11).
Funding
Monika Kutzner Stiftung, Berlin (D.W.), W. Vaillant Stiftung (C.M.)
Received: 22 November 2016   Accepted: 25 January 2017
References
 1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, 
Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of 
the central nervous system. Acta Neuropatholigica. 2007;114(2):97–109.
 2. Ohgaki H, Kleihues P. Population‑based studies on incidence, survival 
rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J 
Neuropathol Exp Neurol. 2005;64(6):479–89.
 3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, 
Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, 
Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, 
Mirimanoff RO. European Organisation for Research and Treatment of 
Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute 
of Canada Clinical Trials Group. Radiotherapy plus concomitant and adju‑
vant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.
 4. Kim SS, Harford JB, Pirollo KF, Chang EH. Effective treatment of glioblas‑
toma requires crossing the blood–brain barrier and targeting tumors 
including cancer stem cells: the promise of nanomedicine. Biochem 
Biophys Res Commun. 2015;468(3):485–9.
 5. Xu YY, Gao P, Sun Y, Duan YR. Development of targeted therapies in treat‑
ment of glioblastoma. Cancer Biol Med. 2015;12(3):223–37.
 6. Reardon DA, Wen PY. Glioma in 2014: unravelling tumour heterogeneity‑
implications for therapy. Nat Rev Clin Oncol. 2015;12(2):69–70.
 7. Cohen AL, Colman H. Glioma biology and molecular markers. Cancer 
Treat Res. 2015;163:15–30.
 8. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, 
Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikol‑
skaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, 
Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin 
R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. 
An integrated genomic analysis of human glioblastoma multiforme. Sci‑
ence. 2008;321(5897):1807–12.
Page 11 of 11William et al. J Transl Med  (2017) 15:27 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 9. Thomas L, Di Stefano AL, Ducray F. Predictive biomarkers in adult gliomas: 
the present and the future. Curr Opin Oncol. 2013;25(6):689–94.
 10. Duncan CG, Yan H. Genomic alterations and the pathogenesis of Glio‑
blastoma. Cell Cycle. 2011;10(8):1174–5.
 11. Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen 
T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, 
Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McClus‑
key CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL, Wen PY. A 
multicenter, phase II, randomized, noncomparative clinical trial of radia‑
tion and temozolomide with or without vandetanib in newly diagnosed 
glioblastoma patients. Clin Cancer Res. 2015;21(16):3610–8.
 12. Chen C, Ravelo A, Yu E, Dhanda R, Schnadig I. Clinical outcomes with 
bevacizumab‑containing and non‑bevacizumab‑containing regimens 
in patients with recurrent glioblastoma from US community practices. J 
Neurooncol. 2015;122(3):595–605.
 13. Westphal M, Heese O, Steinbach JP, Schnell O, Schackert G, Mehdorn M, 
Schulz D, Simon M, Schlegel U, Senft C, Geletneky K, Braun C, Hartung JG, 
Reuter D, Metz MW, Bach F, Pietsch T. A randomised, open label phase III 
trial with nimotuzumab, an anti‑epidermal growth factor receptor mono‑
clonal antibody in the treatment of newly diagnosed adult glioblastoma. 
Eur J Cancer. 2015;51(4):522–32.
 14. Mullins CS, Schneider B, Stockhammer F, Krohn M, Classen CF, Lin‑
nebacher M. Establishment and characterization of primary GBM cell 
lines from fresh and frozen material: a detailed comparison. PloS ONE. 
2013;8(8):e71070.
 15. Voskoglou‑Nomikos T, Pater JL, Seymour L. Clinical predictive value of the 
in vitro cell line, human xenograft, and mouse allograft preclinical cancer 
models. Clin Cancer Res. 2003;9:4227–39.
 16. Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS, 
Bigner DD. Characterization of the epidermal growth factor receptor in 
human glioma cell lines and xenografts. Cancer Res. 1990;50:8017–22.
 17. Romaguera‑Ros M, Peris‑Celda M, Oliver‑De La Cruz J, Carrión‑Navarro 
J, Pérez‑García A, García‑Verdugo JM, Ayuso‑Sacido A. Cancer‑initiating 
enriched cell lines from human glioblastoma: preparing for drug discov‑
ery assays. Stem Cell Rev. 2012;8:288–98.
 18. Joo KM, Kim J, Jin J, Kim M, Seol HJ, Muradov J, Yang H, Choi YL, Park WY, 
Kong DS, Lee JI, Ko YH, Woo HG, Lee J, Kim S, Nam DH. Patient‑specific 
orthotopic glioblastoma xenograft models recapitulate the histopathol‑
ogy and biology of human glioblastomas in situ. Cell Rep. 2013;3:260–73.
 19. Huszthy PC, Daphu I, Niclou SP, Stieber D, Nigro JM, Sakariassen PØ, 
Miletic H, Thorsen F, Bjerkvig R. In vivo models of primary brain tumors: 
pitfalls and perspectives. Neuro‑oncology. 2012;14:979–93.
 20. Fichtner I, Slisow W, Gill J, Becker M, Elbe B, Hillebrand T, Bibby M. Antican‑
cer drug response and expression of molecular markers in early‑passage 
xenotransplanted colon carcinomas. Eur J Cancer. 2004;40:298–307.
 21. Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker 
M, Merk J. Establishment of patient‑derived non‑small cell lung cancer 
xenografts as models for the identification of predictive biomarkers. Clin 
Cancer Res. 2008;14(20):6456–68.
 22. Linnebacher M, Maletzki C, Ostwald C, Klier U, Krohn M, Klar E, Prall F. 
Cryopreservation of human colorectal carcinomas prior to xenografting. 
BMC Cancer. 2010;8:362.
 23. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danen‑
berg PV, Laird PW. MethyLight: a high‑throughput assay to measure DNA 
methylation. Nucl Acids Res. 2000;28(8):E32.
 24. Masibay A, Mozer TJ, Sprecher C. Promega corporation reveals primer 
sequences in its testing kits. J Forensic Sci. 2000;45(6):1360–2.
 25. Cardiff RD, Miller CH, Munn RJ. Manual hematoxylin and eosin staining of 
mouse tissue sections. Cold Spring Harb Protoc. 2014. doi:10.1101/pdb.
prot073411.
 26. Behrens D, Rolff J, Hoffmann J. Predictive in vivo models for oncology. 
Handb Exp Pharmacol. 2016;232:203–21.
 27. Mullins CS, Bock S, Krohn M, Linnebacher M. Generation of xenotrans‑
plants from human cancer biopsies to assess anti‑cancer activities of 
HDACi. Methods Mol Biol. 2017;1510:217–29.
 28. Carlson BL, Pokorny JL, Schroeder MA, Sarkaria JN. Establishment, 
maintenance and in vitro and in vivo applications of primary human 
glioblastoma multiforme (GBM) xenograft models for translational 
biology studies and drug discovery. Curr Protoc Pharmacol. 2011. 
doi:10.1002/0471141755.ph1416s52.
 29. Hatanpaa KJ, Burma S, Zhao D, Habib AA. Epidermal growth factor 
receptor in glioma: signal transduction, neuropathology, imaging, and 
radioresistance. Neoplasia. 2010;12(9):675–84.
 30. Cloughesy TF, Paul S, Mischel PS. Molecular targeting of Glioblastoma—
how do you hit a moving target? Clin Cancer Res. 2011;17(1):6–11.
 31. Reardon DA, Wen PY. Therapeutic advances in the treatment of glio‑
blastoma: rationale and potential role of targeted agents. Oncologist. 
2006;11(2):152–64.
 32. Peters KB, Lou E, Desjardins A, Reardon DA, Lipp ES, Miller E, Herndon JE 
2nd, McSherry F, Friedman HS, Vredenburgh JJ. Phase II trial of upfront 
bevacizumab, irinotecan, and temozolomide for unresectable glioblas‑
toma. Oncologist. 2015;20(7):727–8.
